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Abstract Absence of the spleen constitutes a risk of
infection caused by encapsulated bacteria. The aim of our
study was to determine the immune response to Haemo-
philus influenzae type-b (Hib) conjugate vaccine (HibCV)
in asplenic individuals, considering the cause of asplenia,
the age when splenectomy was carried out, and previous
Hib vaccinations. Twenty asplenic patients, aged five to 25
years, were immunized with a single dose of HibCV. The
specific antibody concentrations against HibCV were
measured by enzyme-linked immunosorbent assay. Before
vaccinations, the geometric mean antibody concentration
(GMC) had an average value of 3.21 μg/ml and was
comparable for all of the patients, regardless of the causes
of asplenia. After vaccinations, the GMC was significantly
higher, with an average of 6.78 μg/ml. Further, 4.5 years
after vaccinations, the GMC was comparable to that of
previously unvaccinated children. Moreover, 17/20 patients
had GMC≥1.0 μg/ml, which included all of the children
with congenital asplenia, children splenectomized before
the age of six years, and only 57% of children
splenectomized after that age. HibCV gives asplenic
patients long-term protection. Hence, HibCV should be
administered regardless of previous vaccinations and
time from splenectomy, even if antibody evaluation is
not available.
Introduction
Before the introduction of Haemophilus influenzae type-b
(Hib) vaccine in national immunization programs, Hib was
a common cause of invasive bacterial diseases and
pneumonia in children under two years of age [1–4]. In
older children, invasive Hib disease occurs less frequently;
however, it has often been a disease of individuals with
immune system dysfunction. An important high-risk group
contracting invasive diseases caused by encapsulated
bacteria (Streptococcus pneumoniae, Hib, and Neisseria
meningitidis) comprises patients with congenital or ac-
quired asplenia and humoral deficiencies [5–7]. This is why
vaccination against Hib, together with immunoprophylaxis
against pneumococcal and meningococcal invasive
i n f e c t i o n s ,i sh i g h l yr e c o m m e n d e di nt h i sg r o u po f
patients [8, 9].
Although the introduction of Hib conjugate vaccines
(HibCVs) in the 1990s fundamentally altered the epidemi-
ology of the Hib disease, it is good to remember that
infections caused by encapsulated bacteria may be observed
in asplenic individuals of any age, even many years after
splenectomy [10].
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asplenic patients to HibCV is scarce and outdated [11, 12].
The aim of our study was to determine the immune
response to HibCV in asplenic children and young adults,
considering the cause of asplenia, the age when splenectomy
was carried out, and previous Hib vaccinations.
Materials and methods
Patients
Twenty asplenic patients, aged five to 25 years (mean: 14.7
years), under the medical care of the Department of
Immunology at the Children’s Memorial Health Institute
in Warsaw, Poland (http://www.immunologia.czd.pl), were
immunized with a single dose of HibCV (ActHIB, Sanofi
Pasteur). The study group consisted of 16 postsplenectomy
patients, three patients with congenital asplenia, and one
patient with spherocytosis. The results of one patient with
spherocytosis, who had been observed to have functional
asplenia since birth, were combined with the results of
patients with congenital asplenia. The main reasons for
splenectomy were abdominal trauma (ten patients), cyst in
the spleen (four patients), portal hypertension, and pancre-
atic tumor (one patient each). Splenectomy had been
conducted in nine children before the age of six years,
and in the remaining patients after the age of six years.
Thirteen patients had been vaccinated against Hib before
taking part in the study (one child was vaccinated in
infancy, and the remainder with one dose after the second
year of life). This vaccination had been administered, on
average, 4.5 years (ranging from one to seven years) before
our test.
The patients were included in our study on the basis of
their medical history and physical examination, and they
were found to be in good health at the time of vaccination.
The test was approved by the Bioethics Committee at the
Children’s Memorial Health Institute, Warsaw, Poland.
Written informed consent was obtained from the patients,
their parents, or their guardians.
Methods
Blood samples were collected just before and one month
after a single dose of HibCV. No other vaccines were given
during the study. The patients were observed for local and
systemic adverse events for a period of 30 min after
vaccination.
The specific Hib antibody concentrations were measured
by enzyme-linked immunosorbent assay at the National
Institute for Health and Welfare, Helsinki, Finland [13].
Antibody levels greater than 0.15 and 1.0 μg/ml are the
minimum protective and the long-term protective concen-
trations, respectively [14, 15].
Statistics
For the quantitative variables, the geometric mean and 95%
confidence intervals were calculated, whereas for the
qualitative variables, the number of patients and percentage
distribution were calculated. The comparison between the
groups was carried out by the Mann–Whitney U-test. For
dependent variables, the Wilcoxon test was used. For the
calculation, a significance level of p<0.05 was assumed as
being statistically significant. The data was processed by
the Polish version of Statistica 6.0.
Results
Before vaccination
In general, before vaccination, the patients had relatively
high antibody concentrations (range: ≤0.15 to 92.7 μg/ml;
geometric mean antibody concentration [GMC]: 3.21 μg/ml).
Concentrations of ≥0.15 μg/ml and ≥1.0 μg/ml were
reached by 17 and 14 patients, respectively (out of 20
each; Table 1)
Thirteen children had been vaccinated against Hib one to
seven years earlier (mean: 4.5 years), according to the
recommended immunization schedule proposed by the
Advisory Committee on Immunization Practices (ACIP)
and other expert committees. Their GMC 4.5 years after
vaccination did not show a statistically significant differ-
ence with reference to the concentrations of previously
unvaccinated children (p=0.75). The proportion of those
patients who had concentrations ≥1.0 μg/ml was similar
regardless of their previous vaccination history (69.2%
versus 71.4%). Interestingly, the three patients who had
GMC ≤0.15 μg/ml had been immunized previously.
All four children with congenital asplenia and spher-
ocytosis, in addition to 10 of the 16 (62.5%) splenectom-
ized children, had antibody concentrations ≥1.0 μg/ml
before vaccination. No statistically significant differences
were found between the GMC levels of these two groups of
patients (p=0.68).
Our patients were divided into two groups on the basis
of the age when splenectomy was conducted. No statisti-
cally significant differences were detected in the antibody
concentrations before vaccinations between the group
containing children with congenital asplenia or those
splenectomized before the sixth year of life and the group
of patients who had splenectomy after the age of six years
(p=0.43), although there was a tendency for lower concen-
trations in the group that had been splenectomized after the
806 Eur J Clin Microbiol Infect Dis (2012) 31:805–809age of six years. Antibody concentrations≤1.0 μg/ml were
found in 3/13 (23.1%) of the patients splenectomized at
ages <6 years and in 3/7 (42.9%) of those splenectomized
at ages >6 years.
After vaccination
No local or systemic adverse events were observed after the
vaccination.
Intheentiregroupof20patients,theGMCwas6.78μg/ml
(range:0.4–107.58μg/ml)aftervaccination.Theincreasewas
modestbut statistically significant, asjudged by the Wilcoxon
signed-rank test (p<0.01; Table 1). In total, five patients
showed a greater-than-two-fold increase in antibody
concentration. All patients had an antibody concentra-
tion ≥0.15 μg/ml, and 17/20 had values ≥1 μg/ml
(Table 1,F i g .1).
The GMC in the group vaccinated previously did not
show any difference compared to the group not vaccinated
before (p=1.0); however, the antibody concentrations were
higher after vaccination than before vaccination in both
groups of patients (p<0.01). All of the three patients who
had levels of ≤0.15 μg/ml before immunization, in addition
to being immunized previously, had an increase in their
antibody concentration after vaccination. Concentration
level ≥1.0 μg/ml was reached in 6/7 and 11/13 patients
who had not been and had been previously vaccinated,
respectively. The GMC in the group of 16 splenectomized
children showed a statistically significant increase (p<0.01),
Table 1 Concentrations of antibodies and protection levels against Haemophilus influenzae type-b (Hib) in the study group before and after
vaccination with Hib conjugate vaccine (HibCV)
Study group Before or after
HibCV vaccination
Antibody concentration (μg/ml) >1 μg/ml (%) >0.15 μg/ml (%)
GMC (95% CI) p-value*
All patients (n=20) Before 3.21 (1.31–7.86) 0.01 70.0 85.0
After 6.78 (3.15–14.62) 85.0 100.0
Previously vaccinated with Hib (n=13) Before 2.69 (0.82–8.80) 0.01 69.2 76.9
After 6.52 (2.57–16.52) 84.6 100.0
Previously not vaccinated with Hib (n=7) Before 4.44 0.74–26.67) 0.01 71.4 100.0
After 7.30 (1.21–44.03) 85.7 100.0
Congenital asplenia (n=4) Before 5.47 (0.25–117.4) 0.07 100.0 100.0
After 7.81 (0.63–131.3) 100.0 100.0
Splenectomy for other reasons (n=16) Before 2.81 (0.99–7.94) 0.01 62.5 81.3
After 6.55 (2.70–15.91) 81.3 100.0
Splenectomized before the age of six years
(n=9) or with congenital asplenia (n=4)
Before 4.10 (1.2–13.56) 0.01 76.9 84.6
After 8.30 (3.69–18.64) 100.0 100.0
Splenectomized after the age of six years (n=7) Before 2.03 (0.37–11.26) 0.01 57.1 85.7
After 4.67 (0.63–34.50) 57.1 100.0
GMC: geometric mean antibody concentration; CI: confidence interval
*Wilcoxon signed-rank test
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Fig. 1 Specific antibody concentrations against Haemophilus influ-
enzae type-b (Hib) before and one month after Hib conjugate vaccine
(HibCV) administration
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asplenia, the difference remained at the border of statistical
significance (p=0.07). There was no difference in anti-
body concentrations after vaccination in these two
groups (p=0.96). All four children with congenital
asplenia had ≥1.0 μg/ml of antibodies both before and
after vaccination. In the case of splenectomized children,
the percentage of patients with ≥1.0 μg/ml of antibodies
increased from 62.5% to 81.3%.
A statistically significant increase was observed in the
postvaccination antibody concentrations in the group of
children with congenital asplenia or splenectomized before
the sixth year of life and in the patients who underwent
splenectomy after the age of six years (p<0.01); moreover,
the postvaccination antibody concentrations were similar
(p=0.53). All 13 children either with congenital asplenia
or who were splenectomized before the age of six years
had an antibody concentration ≥1.0 μg/ml after vaccination,
whereas in the group of seven children splenectomized after
the sixth year of life, the proportion was 4: 7.
Discussion
HibCV has been confirmed to be effective for healthy
children [2, 16, 17]. Our research shows that HibCV is
immunogenic in asplenic children and young adults;
however, the measured immune response is only modest.
One reason for the modest immune response can be that the
concentrations of antibodies against Hib were relatively
high even before vaccination, in both previously vaccinated
and unvaccinated patients, probably due to the circulation
of Hib in our population and the lack of compulsory Hib
vaccination before 2007 in the Polish immunization
schedule. Another possible reason is cross-reactivity from
other bacteria [18].
Evenifthe responsetoHib vaccination was onlymodest,it
increased the proportion of patients with supposed protective
concentrations, so that all had levels >0.15 μg/ml, and only
threepatientshadlevels<1.0μg/ml.Thisincreaseofantibody
concentration was observed independently of the previous
Hib vaccinations. All of the four patients with congenital
asplenia or spherocytosis already had high antibody concen-
trations before vaccination (range: 1.34–92.97 μg/ml) and did
n o th a v ea ni n c r e a s ea f t e r w a r d s( T a b l e1), whereas many
patients with splenectomy clearly benefited from the
vaccination (Table 1), especially those with low antibody
concentrations prevaccination (Fig. 1).
Opinion-making groups (World Health Organization;
American Academy of Pediatrics; and immunization pro-
grams in countries of the European Union) recommend Hib
vaccination for healthy children before the age of six years
[19–21], as the age of the patient may be the basic factor
influencing vaccine efficacy. In our study, a considerable
postvaccination increase of antibody concentrations was
observed in patients splenectomized before and after the
age of six years. In the group of seven patients splenec-
tomized after the sixth year of life, a subgroup of three
children had concentrations <1.0 μg/ml before vaccina-
tion, which remained at the same level after vaccination,
whereas all those who were splenectomized before six
years of age or had congenital asplenia showed antibody
levels >1.0 μg/ml after vaccination. Thus, our data
suggest lower vaccine efficacy for children splenectom-
ized after the age of six years.
It is also worth noting that the mean antibody concen-
trations in the pre- and postvaccination sera of patients
vaccinated against Hib (on average, 4.5 years previously)
were similar to those of patients who had not received
HibCV before entering this study. In fact, all of the patients
who had levels ≤0.15 μg/ml before vaccination had
undergone vaccination previously. This suggests that
immunization with HibCV might not offer persistent protec-
tion in this patient group and that vaccination later in life,
regardless of previous vaccination status, would be useful.
Regardless of whether the children had previously been
vaccinated or not, approximately 30% of the analyzed
patients did not possess antibodies >1.0 μg/ml and might
potentially have been susceptible to invasive infection with
Haemophilus influenzae. In an unmatched case–control
study, McVernon et al. showed that the GMCs of convales-
cent Hib antibodies were comparable between immunized
and unimmunized children, using both raw and adjusted
data [22]. The GMC assessed after the vaccinations in both
of these groups was statistically higher than that before the
vaccinations, and the seroprotection level was 85%. Our
study indicates that, in asplenic patients, a subsequent
vaccination, regardless of whether there had been previous
vaccinations or not, is immunogenic.
In the patients previously vaccinated against Hib,
reimmunization increased the antibody concentration and
the level of seroprotection. Therefore, an additional dose of
Hib vaccine should be administered to those asplenic
patients whose postvaccination antibody concentration is
below 1.0 μg/ml. Consequently, a decision as to whether to
revaccinate should be taken individually for each patient,
ideally after assessing the patient’s antibody concentration.
However, considering the low reactogenicity of HibCV
[17] and the lack of access to the assessment of postvac-
cination antibodies, our study suggests that, regardless of
the history of vaccinations against Hib, revaccination
increases antibody titers, thus, providing protection. Revac-
cination with Hib is not recommended for asplenic
individuals at present [5]. Our results indicate that, in the
case of asplenic patients, a previously administered vaccine
against Hib does not ensure a long-lasting protective level
808 Eur J Clin Microbiol Infect Dis (2012) 31:805–809of antibodies, suggesting a need for revaccination with
HibCV in the group of asplenic patients, despite the routine
immunoprophylaxis of Hib in infancy.
Conclusion
Haemophilus influenzae type-b (Hib) conjugate vaccine
(HibCV) increases antibody concentrations in asplenic
patients, and most of these patients have antibody levels
greater than 1.0 μg/ml after vaccination. Therefore, HibCV
should be administered regardless of previous vaccinations
and the time that has elapsed after splenectomy, even if
antibody evaluation is not available.
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